CONTENTS:
• Editorial: Russia and human immunodeficiency virus- beyond crime and punishment. Samet J.H., p. 1883-1885.
• FOR DEBATE: Basing drug scheduling decisions on scientific ranking of harmfulness: false promise from false premises. Caulkins J.P., Reuter P., Coulson C., p. 1886-1890.
COMMENTARIES:
• Nutt et al.'s harm scales for drugs-room for improvement but better policy based on science with limitations than no science at all. Fischer B., Kendall P., p. 1891-1892.
• Let not the best be the enemy of the good. Nutt D., p. 1892-1893.
• Can harm ratings be useful? Rossow I., p. 1893-1894.
• Improved ranking of drugs on harmfulness can bring sense and order to a failed system. Obot I.S., p. 1894-1895.
• Scales and blinkers, motes and beams - whose view is obstructed on drug scheduling? Room R., p. 1895-1896.
• Response to commentaries. Caulkins J.P., Reuter P., Coulson C., p. 1896-1898.
• What can we learn from the Dutch cannabis coffeeshop system? Maccoun R.J., p. 1899-1910.
• A systematic review of methamphetamine precursor regulations. McKetin R., Sutherland R., Bright D.A., Norberg M.M., p. 1911-1924.
• Housewife or working mum-each to her own? The relevance of societal factors in the association between social roles and alcohol use among mothers in 16 industrialized countries. Kuntsche S., Knibbe R.A., Kuntsche E., Gmel G., p. 1925-1932.
• Commentary on Kuntsche et al. (2011): Mothers and bottles - the role of gender norms in shaping drinking. Armstrong E.M., p. 1933-1934.
• DSM-IV to DSM-5: the impact of proposed revisions on diagnosis of alcohol use disorders. Agrawal A., Heath A.C., Lynskey M.T., p. 1935-1943.
• Commentary on Agrawal et al. (2011): Assessing the impact of changes to diagnostic criteria on the estimated prevalence of alcohol use disorders in general population surveys. Slade T., Teesson M., Carragher N., Farrell M., p. 1944-1945.
• Drinking behaviour among men and women in China: the 2007 China Chronic Disease and Risk Factor Surveillance. Li Y., Jiang Y., Zhang M., Yin P., Wu F., Zhao W., p. 1946-1956.
• The role of alcohol in the Russian mortality crisis. Norstrom T., p. 1957-1965.
• The effect of neighborhood deprivation and residential relocation on long-term injection cessation among injection drug users (IDUs) in Baltimore, Maryland. Genberg B.L., Gange S.J., Go V.F., Celentano D.D., Kirk G.D., Latkin C.A., et al., p. 1966-1974.
• Commentary on Genberg et al. (2011): The structural vulnerability imposed by hypersegregated US inner-city neighborhoods - a theoretical and practical challenge for substance abuse research. Bourgois P., Hart L.K., p. 1975-1977.
• The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. Turner K.M., Hutchinson S., Vickerman P., Hope V., Craine N., Palmateer N., et al., p. 1978-1988.
• Commentary on Turner et al. (2011): Significant global scale-up of harm reduction interventions and pragmatic research approaches needed to prevent hepatitis C transmission. Day C., Topp L., p. 1989-1990.
• Mephedrone: use, subjective effects and health risks. Winstock A., Mitcheson L., Ramsey J., Davies S., Puchnarewicz M., Marsden J., p. 1991-1996.
• Long-term effects of a community-based intervention: 5-year follow-up of 'Clubs against Drugs'. Abdon J.G., Wallin E., Andreasson S., p. 1997-2004.
• Planned quit attempts among Ontario smokers: impact on abstinence. Sendzik T., McDonald P.W., Brown K.S., Hammond D., Ferrence R., p. 2005-2013.
• What do we know about unplanned quit attempts? Practically nothing or nothing practical? Prochaska J.O., p. 2014-2015.
• A response to prochaska: life does not always go according to plan; your quitting might not either. Sendzik T., McDonald P.W., Brown K.S., Hammond D., Ferrence R., p. 2015-2016.
• Electronic cigarette: users profile, utilization, satisfaction and perceived efficacy. Etter J.F., Bullen C., p. 2017-2028.
• Commentary on Etter & Bullen (2011): Could E-cigs become the ultimate nicotine maintenance device? Foulds J., Veldheer S., p. 2029-2030.
• The timing of smoking onset, prolonged abstinence and relapse in men: a prospective study from ages 18 to 32 years. Kerr D.C., Owen L.D., Capaldi D.M., p. 2031-2038.
• Statistical analysis of daily smoking status in smoking cessation clinical trials. Li Y., Wileyto E.P., Heitjan D.F., p. 2039-2046.
• Reversing the taxes approach for a win-win tobacco control policy. Braillon A., p. 2047.
• Equity considerations in the calculation of cost-effectiveness in substance use disorder populations. Gilmour S.J., p. 2047-2048.